Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial.
BMC Endocr Disord. 2019 Jan 18;19(1):8. doi: 10.1186/s12902-019-0337-8.
Hammami MM1,2, Abuhdeeb K3, Hammami S4, Yusuf A3.
Vitamin D3 instead of D2 category in VitaminDWiki starts with
Some of the- Overview Vitamin D3 not D2
- Physicians Desk Reference still only lists D2, but not Vitamin D3 – Feb 2022
- Vitamin D3 better than D2, especially if non-daily or high dose - meta-analysis Sept 2021
- It’s Time to Say “Goodbye” to Vitamin D2 - 2015
- Vitamin D2 decreases levels of D3 (again) and visa versa – RCT Jan 2019
- It’s (way past) time to stop prescribing with Vitamin D2 (ergocalciferol) – Oct 2018
- If you have a vitamin D prescription, be sure that it is for D3– June 2017
- Vitamin D reduces risk of cause specific death, unless it is D2 – meta-analysis BMJ April 2014
- Vitamin D2 should not be used as a Vitamin supplement for any mammal – Oct 2006
- Loading dose of Vitamin D2 REDUCED vitamin D blood in a third of the patients – Jan 2015
Download the PDF from VitaminDWiki
BACKGROUND:
Vitamin-D2 (D2) treatment has been associated with a decrease in 25-hydroxy OH vitamin-D3 (D3) level, suggesting that D3 treatment would be preferred to raise total 25(OH) vitamin-D (D) level. We postulated that D2 treatment-associated decrease in 25(OH)D3 level is related to the increase in 25(OH)D level rather than being D2-specific, and thus there would be a similar D3 treatment-associated decrease in 25(OH)D2 level.
METHODS:
Fifty volunteers were block-randomized to 50,000 IU D2 or placebo orally once (study-1) and fifty volunteers received 50,000 IU D2 orally once and 4 days later block-randomized to 50,000 IU D3 or placebo orally once (study-2). Interventions were concealed from volunteers and research coordinators and blindly-administered. Serum 25(OH)D2 and 25(OH)D3 levels were blindly-determined at baseline and days 14, 28, 42, and 56, post-randomization by high performance liquid chromatography assay. Results of 97 participants were analyzed. Primary outcome measure was day-28 D2-associated change in 25(OH)D3 level in study-1 and D3-associated change in 25(OH)D2 level in study-2, adjusted for baseline levels.
RESULTS:
Mean (95% confidence interval) difference between the active and placebo arms in the decrease in day-28 25(OH)D3 (study-1) and 25(OH)D2 (study-2) levels was 13.2 (9.7 to 16.6) and 9.8 (5.2 to 14.4) nmol/L, respectively. Corresponding differences at day-56 were 10.8 (6.8 to 14.8) and 1.7 (- 7.6 to 11.1) nmol/L, respectively. The difference between the placebo and active arms in area-under-the-curve at day-28 (AUC28) and day-56 (AUC56) were 262.3 (197.8 to 326.7) and 605.1 (446.3 to 784.0) for 25(OH)D3 (study-1) and 282.2 (111.2 to 453.3) and 431.2 (179.3 to 683.2) nmol.d/L for 25(OH)D2 (study-2), respectively. There were significant correlations between day-28 changes in 25(OH)D2 and 25(OH)D3 levels in study-1 (rho = - 0.79, p < 0.001) and study-2 (rho = - 0.36, p = 0.01), and between day-28 changes in 25(OH)D2 level and baseline 25(OH)D level in study-2 (rho = - 0.42, p = 0.003).
CONCLUSIONS:
Compared to placebo, D3 treatment is associated with a decrease in 25(OH)D2 level similar in magnitude to D2-treatment associated decrease in 25(OH)D3 level; however, the D3-placebo difference in 25(OH)D2 level is shorter-lasting. Changes in 25(OH)D2 and 25(OH)D3 levels are correlated with each other and with baseline 25 (OH) D levels, suggesting a common regulatory mechanism.
TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT03035084 (registered January 27, 2017).
| 2599 visitors, last modified 24 Aug, 2021, |